Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Defibrotide (Defitelio) for prevention and treatment of respiratory distress and cytokine release syndrome in hospitalized COVID-19 patients
2020-001409-21Phase 2Active
- Sponsor
- Foundation for Food & Agriculture Research
- Start
- Apr 2020
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Defitelio arm with Placebo arm (2 arms). Primary endpoint: 30-day all-cause mortality. Started Apr 2020; status: active.
02
Drugs
defibrotide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001409-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001409-21.